David Hughes, PharmD, BCOP | Authors

Expert Commentary on the Product Profile of Tepotinib

November 14, 2021

In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.